Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kyle M Carter

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Frontiers in Genetics|April 2, 2020
An Information-Based Approach for Mediation Analysis on High-Dimensional Metagenomic DataKyle M Carter, Meng Lu, Hongmei Jiang, et al.
Plos One|July 24, 2020
Microbial community dissimilarity for source tracking with application in forensic studiesKyle M Carter, Meng Lu, Qianwen Luo, et al.
RMD Open|July 26, 2024
Efficacy and safety of upadacitinib in patients with rheumatoid arthritis and inadequate response or intolerance to biological treatments: results through 5 years from the SELECT-BEYOND studyRoy Fleischmann, Sebastian Meerwein, Christina Charles-Schoeman, et al.
RMD Open|May 11, 2025
Upadacitinib as monotherapy in patients with rheumatoid arthritis and prior inadequate response to methotrexate: results at 260 weeks from the SELECT-MONOTHERAPY randomised studyJosef S Smolen, Paul Emery, William Rigby, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Frontiers in Genetics|April 2, 2020
An Information-Based Approach for Mediation Analysis on High-Dimensional Metagenomic DataKyle M Carter, Meng Lu, Hongmei Jiang, et al.
Plos One|July 24, 2020
Microbial community dissimilarity for source tracking with application in forensic studiesKyle M Carter, Meng Lu, Qianwen Luo, et al.
RMD Open|July 26, 2024
Efficacy and safety of upadacitinib in patients with rheumatoid arthritis and inadequate response or intolerance to biological treatments: results through 5 years from the SELECT-BEYOND studyRoy Fleischmann, Sebastian Meerwein, Christina Charles-Schoeman, et al.
RMD Open|May 11, 2025
Upadacitinib as monotherapy in patients with rheumatoid arthritis and prior inadequate response to methotrexate: results at 260 weeks from the SELECT-MONOTHERAPY randomised studyJosef S Smolen, Paul Emery, William Rigby, et al.
Pageof 1